Special Issue "Hepatitis C Virus: Remaining Challenges"
Deadline for manuscript submissions: 31 December 2021.
Since its discovery in 1989, remarkable progress has been made in the understanding of hepatitis C virus (HCV) infection, culminating in the approval of highly effective direct-acting antivirals (DAAs). It has been an outstanding success story. However, DAA access is still limited for the majority of patients, and approximately 70 million people around the world are still chronically infected with HCV and at increased risk for severe liver disease and liver cancer. An effective vaccine will likely be necessary to achieve global elimination of HCV. The development of strategies to mitigate HCV-associated liver disease would also have a major impact on global health. Therefore, despite the tremendous success of DAAs, there are still challenges that remain to be addressed. Moreover, HCV research has contributed greatly to the understanding of fundamental processes in cell biology. The study of HCV virus-host interactions remains highly relevant to dissect fundamental mechanisms of immune evasion and liver disease pathogenesis, and to further understand basic cell biology, including the regulation of lipid membrane homeostasis and the roles of microRNAs in cellular processes.
This Special Issue aims to provide a comprehensive overview of the state-of-the-art of HCV infection, covering a wide range of topics ranging from molecular virology to disease pathogenesis to the latest in HCV treatment and prevention. Submissions in any of these areas are welcomed, including review articles that highlight the achievements and remaining challenges, and research articles focusing on ongoing efforts in the HCV field.
Dr. Che Colpitts
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hepatitis C virus
- virus-host interactions
- lipid membranes
- adaptive immunity
- innate immunity
- viral evasion
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.